Page last updated: 2024-10-23

bisbenzimidazole and Fanconi Anemia

bisbenzimidazole has been researched along with Fanconi Anemia in 1 studies

Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.

Fanconi Anemia: Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wolff, S1

Reviews

1 review available for bisbenzimidazole and Fanconi Anemia

ArticleYear
Sister chromatid exchange.
    Annual review of genetics, 1977, Volume: 11

    Topics: Ataxia Telangiectasia; Autoradiography; Azure Stains; Bisbenzimidazole; Carcinogens; Cell Division;

1977